Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0L5GH
|
|||
Former ID |
DCL000187
|
|||
Drug Name |
Olcegepant
|
|||
Synonyms |
Olcegepant [INN]; BIBN 4096; BIBN 4096 BS; BIBN-4096; BIBN-4096BS; N-((1R)-2-(((1S)-5-Amino-1-((4-(pyridin-4-yl)piperazin-1-yl)carbonyl)pentyl)amino)-1-(3,5-dibromo-4-hydroxybenzyl)-2-oxoethyl)-4-(2-oxo-1,4-dihydroquinazolin-3(2H)-yl)piperidine-1-carboxamide; N-[(2R)-1-[[(2S)-6-amino-1-oxo-1-(4-pyridin-4-ylpiperazin-1-yl)hexan-2-yl]amino]-3-(3,5-dibromo-4-hydroxyphenyl)-1-oxopropan-2-yl]-4-(2-oxo-1,4-dihydroquinazolin-3-yl)piperidine-1-carboxamide
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Migraine [ICD-11: 8A80; ICD-10: G43, G43.9; ICD-9: 346] | Phase 2 | [1], [2] | |
Company |
Boehringer Ingelheim
|
|||
Structure |
Download2D MOL |
|||
Formula |
C38H47Br2N9O5
|
|||
Canonical SMILES |
C1CN(CCC1N2CC3=CC=CC=C3NC2=O)C(=O)NC(CC4=CC(=C(C(=C4)Br)O)Br)C(=O)NC(CCCCN)C(=O)N5CCN(CC5)C6=CC=NC=C6
|
|||
InChI |
1S/C38H47Br2N9O5/c39-29-21-25(22-30(40)34(29)50)23-33(45-37(53)48-15-10-28(11-16-48)49-24-26-5-1-2-6-31(26)44-38(49)54)35(51)43-32(7-3-4-12-41)36(52)47-19-17-46(18-20-47)27-8-13-42-14-9-27/h1-2,5-6,8-9,13-14,21-22,28,32-33,50H,3-4,7,10-12,15-20,23-24,41H2,(H,43,51)(H,44,54)(H,45,53)/t32-,33+/m0/s1
|
|||
InChIKey |
ITIXDWVDFFXNEG-JHOUSYSJSA-N
|
|||
CAS Number |
CAS 204697-65-4
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Calcitonin gene-related peptide receptor (CGRPR) | Target Info | Modulator | [3] |
KEGG Pathway | Neuroactive ligand-receptor interaction | |||
Vascular smooth muscle contraction | ||||
Reactome | G alpha (s) signalling events | |||
Calcitonin-like ligand receptors | ||||
WikiPathways | GPCRs, Class B Secretin-like | |||
Endothelin Pathways | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 702). | |||
REF 2 | ClinicalTrials.gov (NCT02198339) Efficacy, Safety, Tolerability and Pharmacokinetics of BIBN 4096 BS Versus Placebo in the Treatment of a Single Attack of Acute Migraine Headache. U.S. National Institutes of Health. | |||
REF 3 | Olcegepant, a non-peptide CGRP1 antagonist for migraine treatment. IDrugs. 2007 Aug;10(8):566-74. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.